PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab:

Skip to Content

Clinical Trial Details

Alliance A031704 “PDIGREE”

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab:

Objective
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr

Clinical Trial Categories

  • Other
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6031